Market Overview
The global iron deficiency anemia treatment market was valued at USD 844 million in 2024 and is projected to reach USD 1089 million by 2031, exhibiting a CAGR of 3.8% during the forecast period.
Iron deficiency anemia treatment encompasses therapeutic interventions aimed at restoring iron levels in patients with insufficient iron stores. The primary treatment modalities include oral iron supplements such as ferrous sulfate, ferrous gluconate, and ferrous fumarate, alongside intravenous iron formulations like ferric hydroxide and sodium ferric gluconate for severe cases.
While oral iron remains the first-line therapy, intravenous options are gaining traction due to improved bioavailability and patient compliance.
USD 844 million in 2024
USD 1089 million by 2031
of 3.8%
Oral Iron Supplements
Intravenous Iron Therapy
Intravenous Iron Therapy is gaining significant traction among healthcare providers due to its higher bioavailability and faster patient recovery times, particularly in cases of severe anemia where oral supplements are insufficient.
By Application
Hospitals and Clinics
Home Healthcare
Specialized Treatment
Retail Pharmacies
Hospitals
https://www.24lifesciences.com
Our Key Players
Vifor Pharma (Switzerland)
American Regent, Inc. (USA)
Pharmacosmos Therapeutics (Denmark)
AMAG Pharmaceuticals (USA)
Akebia Therapeutics (USA)
Rockwell Medical (USA)
https://www.24lifesciences.com
